Clinicians around the world use NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) as a standard for clinical decision-making.  The NCCN Harmonized Guidelines™ are targeted regional resources created as part of a collaborative effort to combat the skyrocketing cancer rate

As research on clinical cancer care rapidly evolves, utilizing and implementing a staging system that is primarily based on prognostic information may have limitations.

Numerous multigene-based assays have been developed to better prognosticate the risk of recurrence and death and predict benefit of therapy.

Surgical management of the axilla and adjuvant systemic therapy strategies have evolved considerably.  A recent survey revealed substantial variation in surgeon management suggesting the potential for overtreatment of many patients and the need for education in this area.

The endocrine therapy options are expanding for patients with early stage and advanced stage disease.

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Locoregional management strategies have considerably evolved.  Although several randomized studies have identified patients that do not need ALND, a recent survey revealed substantial variation in surgeon management suggesting the potential for overtreatment of many patients and the need for educ

With the release of the 8th edition of the AJCC staging manual,  it is important for clinicians to be aware of the updates to the AJCC TNM staging in order to select appropriate treatment, evaluate treatment outcomes, participate in clinical trials, and facilitate accurate information sharing amo